drugset
Drugs / InvaplexAR-Detox
last change May 2025 re-read 3 minutes ago

InvaplexAR-Detox

Vaccine

Developed for
diarrheal disease · shigellosis
Investigated by
PATH · Centre for Infectious Disease Research in Zambia · European Vaccine Initiative · European and Developing Countries Clinical Trials Partnership (EDCTP) · Göteborg University · Leiden University Medical Center
+1 more · Walter Reed Army Institute of Research (WRAIR)

Trials 2

today NCT05961059 · Ph 1 NCT03869333 · Ph 1
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05961059 Oct 2024 → May 2025 overdue shigellosis Leiden University Medical Center Recruiting No outcome recorded
Phase 1 NCT03869333 Mar 2019 → Jun 2020 diarrheal disease PATH Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as InvaplexAR-Detox ClinicalTrials.gov intervention name — accepted as the source's own label NCT05961059 ↗
1

NCT03869333 ↗
Modality Vaccine “Detoxified Shigella Flexneri 2a Artificial Invasin Complex (Invaplex[AR-DETOX]) Vaccine” NCT03869333 ↗
Route Intramuscular “The vaccine will be administered via intramuscular (IM) injection on study days 1, 22, and 43.” NCT03869333 ↗